Last updated: Monday, 25, October, 2010
|Key Information||Appropriate Tests|
FBC, blood film, differential WCC; bone marrow aspiration and trephine biopsy.
Cytochemistry, cytogenetics (oncology), blast cell immunophenotyping and molecular genetics on blood andor bone marrow aspirate to classify type.
The WHO classification is based on the FAB classification of acute leukaemia. It incorporates morphologic, immunophenotypic, genetic and clinical features in an attempt to define entities that are biologically homogeneous and that have clinical relevance. The acute leukaemias are classified as myeloid or lymphoid based on the lineage of the blast cells. This is based on morphology of blood and bone marrow aspirate, cytochemistry, electron microscopy and cell immunophenotyping; it guides therapy and indicates prognosis.
Acute myeloid leukemias
AMLs with recurrent cytogenic abnormalities
AML with multilineage dysplasiaAML and myelodysplastic syndrome, therapy related
AML, not otherwise categorised
Acute lymphoblastic leukemias
Acute lymphoblastic leukaemia may be of pre-B cell, B cell, precursor B cell, or T cell origin.
Acute leukemias of ambiguous lineage
aListed in WHO classification under precursor B-cell and T-cell neoplasms.
Bone marrow failure
See Febrile neutropenia.
Especially is acute promyelocytic leukaemia
FBC; thrombin time, fibrin degradation products, APTT, PT, fibrinogen.
Acute promyelocytic leukaemia, especially
Leukostasis (especially in acute myeloblastic leukaemia)
With extreme leucocytosis (blast cells).
Urate nephropathy, especially in
See Renal failure - acute.